Arcutis Biotherapeutics (ARQT) revenue breakdown
By product, ZORYVE foam is the largest at 49% of fiscal 2025 revenue; ZORYVE cream 0.15% grew fastest, 588% a year over 1 years.
Revenue by product
Fiscal years, as Arcutis Biotherapeutics reports them in its 10-K filings; fiscal 2025 total $372M.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| ZORYVE foam | — | $72M | $182M | 49% |
| ZORYVE cream 0.3% | — | $85M | $121M | 33% |
| ZORYVE cream 0.15% | — | $10M | $68M | 18% |
| ZORYVE cream 0.05% | — | — | $911,000 | 0% |
| Other revenue | $30M | — | — | — |
| Product revenue, net | $29M | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ARQT.
Open ARQT in InvestinglyQuestions
Where does Arcutis Biotherapeutics make its money?
In fiscal 2025, by product: ZORYVE foam $182M, ZORYVE cream 0.3% $121M, ZORYVE cream 0.15% $68M, ZORYVE cream 0.05% $911,000.
From Arcutis Biotherapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.